Skip to main content
Top
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvant chemo-radiotherapy

Authors: Pierina Navarria, Federico Pessina, Luca Cozzi, Anna Maria Ascolese, Francesca Lobefalo, Antonella Stravato, Giuseppe D’Agostino, Ciro Franzese, Manuela Caroli, Lorenzo Bello, Marta Scorsetti

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

To assess the impact of volumetric-modulated arc therapy (VMAT) compared with 3D-conformal radiotherapy (3DCRT) in patients with newly diagnosed high grade glioma in terms of toxicity, progression free survival (PFS) and overall survival (OS).

Methods

From March 2004 to October 2014, 341 patients underwent surgery followed by concomitant and adjuvant chemo-radiotherapy. From 2003 to 2010, 167 patients were treated using 3DCRT; starting from 2011, 174 patients underwent VMAT. The quantitative evaluation of the treatment plans was performed by means of standard dose volume histogram analysis. Response was recorded using the Response Assessment in Neuro-Oncology (RANO) criteria and toxicities graded according to Common Terminology Criteria for Adverse Event version 4.0.

Results

Both techniques achieved an adequate dose conformity to the target. The median follow up time was 1.3 years; at the last observation 76 patients (23.4 %) were alive and 249 (76.6 %) dead (16 patients were lot to follow-up). For patients who underwent 3DCRT, the median PFS was 0.99 ± 0.07 years (CI95: 0.9–1.1 years); the 1 and 3 years PFS were, 49.6 ± 4 and 19.1 ± 3.1 %. This shall be compared, respectively, to 1.29 ± 0.13 years (CI95: 1.01–1.5 years), 60.8 ± 3.8, and 29.7 ± 4.6 % for patients who underwent VMAT (p = 0.02). The median OS for 3DCRT patients was 1.21 ± 0.09 years (CI95:1.03–1.3 years); 1 and 5 year OS was, 63.3 ± 3.8 and 21.5 ± 3.3 %. The corresponding results for 3DRCT patients were 1.56 ± 0.09 years (CI95:1.37–1.74 years), 73.4 ± 3.5, 30 ± 4.6 % respectively (p < 0.01). In both groups, prognostic factors conditioning PFS and OS were age, gender, KPS, histology and extent of resection (EOR).

Conclusions

VMAT resulted superior to 3DCRT in terms of dosimetric findings and clinical results.
Literature
1.
go back to reference Stupp R, Hegi M, Mason W, van den Bent MJ, Tahpoorn M, Janzer R, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.CrossRefPubMed Stupp R, Hegi M, Mason W, van den Bent MJ, Tahpoorn M, Janzer R, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.CrossRefPubMed
2.
go back to reference Scoccianti S, Magrini S, Ricardi U, Detti B, Krengli M, Parisi S, et al. Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multi center study by the central nervous system study group of AIRO (Italian association of radiation oncology). Neuro Oncol. 2012;14:798–807.CrossRefPubMedPubMedCentral Scoccianti S, Magrini S, Ricardi U, Detti B, Krengli M, Parisi S, et al. Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multi center study by the central nervous system study group of AIRO (Italian association of radiation oncology). Neuro Oncol. 2012;14:798–807.CrossRefPubMedPubMedCentral
3.
go back to reference Combs S, Nagy M, Edler L, Rausch R, Bischof M, Welzel T, et al. Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors. Radiother Oncol. 2008;88:177–82.CrossRefPubMed Combs S, Nagy M, Edler L, Rausch R, Bischof M, Welzel T, et al. Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors. Radiother Oncol. 2008;88:177–82.CrossRefPubMed
4.
go back to reference Brandes A, Nicolardi L, Tosoni A, Gardiman M, Iuzzolino P, Ghimenton C, et al. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol. 2006;8:253–60.CrossRefPubMedPubMedCentral Brandes A, Nicolardi L, Tosoni A, Gardiman M, Iuzzolino P, Ghimenton C, et al. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol. 2006;8:253–60.CrossRefPubMedPubMedCentral
5.
go back to reference Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. J Clin Oncol. 2009;35:5874–80.CrossRef Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. J Clin Oncol. 2009;35:5874–80.CrossRef
6.
go back to reference Chan J, Lee S, Fraass B, Normolle d, Greenberg H, Junck L, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol. 2002;20:1635–42.CrossRefPubMed Chan J, Lee S, Fraass B, Normolle d, Greenberg H, Junck L, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol. 2002;20:1635–42.CrossRefPubMed
7.
go back to reference Garden A, Maor M, Yung W, Bruner J, Woo s, Moser R, et al. Outcome and patterns of failure following limited volume irradiation for malignant astrocytomas. Radiother Oncol. 1991;20:99–110.CrossRefPubMed Garden A, Maor M, Yung W, Bruner J, Woo s, Moser R, et al. Outcome and patterns of failure following limited volume irradiation for malignant astrocytomas. Radiother Oncol. 1991;20:99–110.CrossRefPubMed
8.
go back to reference Hess C, Schaaf J, Kortmann R, Schabet M, Bamberg M. Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol. 1994;30:146–9.CrossRefPubMed Hess C, Schaaf J, Kortmann R, Schabet M, Bamberg M. Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol. 1994;30:146–9.CrossRefPubMed
9.
go back to reference Navarria P, Reggiori G, Pessina F, Ascolese A, Tomatis S, Mancosu P, et al. Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma. Radiothe Oncol. 2014;112:425–9.CrossRef Navarria P, Reggiori G, Pessina F, Ascolese A, Tomatis S, Mancosu P, et al. Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma. Radiothe Oncol. 2014;112:425–9.CrossRef
10.
go back to reference Combs S, Gutwein S, Thilmann C, Debus J, Schulz-Ertner D. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J Neurooncol. 2005;74:167–71.CrossRefPubMed Combs S, Gutwein S, Thilmann C, Debus J, Schulz-Ertner D. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J Neurooncol. 2005;74:167–71.CrossRefPubMed
11.
go back to reference Combs S, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D. Stereotactic radiosurgery (SRS)-treatment option for recurrent glioblastoma multiforme (GBM). Cancer. 2005;104:2168–73.CrossRefPubMed Combs S, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D. Stereotactic radiosurgery (SRS)-treatment option for recurrent glioblastoma multiforme (GBM). Cancer. 2005;104:2168–73.CrossRefPubMed
12.
go back to reference Biswas T, Okunieff P, Schell M, Smudzin T, Pilcher W, Bakos R, et al. Stereotactic radiosurgery for glioblastoma: retrospective analysis. Radiat Oncol. 2009;4:11.CrossRefPubMedPubMedCentral Biswas T, Okunieff P, Schell M, Smudzin T, Pilcher W, Bakos R, et al. Stereotactic radiosurgery for glioblastoma: retrospective analysis. Radiat Oncol. 2009;4:11.CrossRefPubMedPubMedCentral
13.
go back to reference Fuller C, Choi M, Forthuber B, Wang S, Rajagiriyil N, Salter B, et al. Standard fractionation intensity modulated radiation therapy (IMRT) of primary, recurrent glioblastoma multiforme. Radiat Oncol. 2007;2:26.CrossRefPubMedPubMedCentral Fuller C, Choi M, Forthuber B, Wang S, Rajagiriyil N, Salter B, et al. Standard fractionation intensity modulated radiation therapy (IMRT) of primary, recurrent glioblastoma multiforme. Radiat Oncol. 2007;2:26.CrossRefPubMedPubMedCentral
14.
go back to reference Vieillot S, Azria D, Lemanski C, Moscardo C, Gourgou S, Dubois J, et al. Plan comparison of volumetric modulated arc therapy (RapidArc) and conventional intensity modulated radiation therapy (IMRT) in anal canal cancer. Radiat Oncol. 2010;5:92.CrossRefPubMedPubMedCentral Vieillot S, Azria D, Lemanski C, Moscardo C, Gourgou S, Dubois J, et al. Plan comparison of volumetric modulated arc therapy (RapidArc) and conventional intensity modulated radiation therapy (IMRT) in anal canal cancer. Radiat Oncol. 2010;5:92.CrossRefPubMedPubMedCentral
15.
go back to reference Clivio A, Fogliata A, Franzetti-Pellanda A, Nicolini G, Vanetti e, Wyttenbach R, et al. Volumetric modulated arc radiotherapy for carcinomas of the anal canal: a treatment planning comparison with fixed field IMRT. Radiother Oncol. 2009;92:118–24.CrossRefPubMed Clivio A, Fogliata A, Franzetti-Pellanda A, Nicolini G, Vanetti e, Wyttenbach R, et al. Volumetric modulated arc radiotherapy for carcinomas of the anal canal: a treatment planning comparison with fixed field IMRT. Radiother Oncol. 2009;92:118–24.CrossRefPubMed
16.
go back to reference Castellano A, Bello L, Michelozzi C, Gallucci M, Fava E, Iadanza A, et al. Role of diffusion tensor magnetic resonance tractography in predicting the extent of resection in glioma surgery. Neuro Oncol. 2012;14:192–202.CrossRefPubMed Castellano A, Bello L, Michelozzi C, Gallucci M, Fava E, Iadanza A, et al. Role of diffusion tensor magnetic resonance tractography in predicting the extent of resection in glioma surgery. Neuro Oncol. 2012;14:192–202.CrossRefPubMed
17.
go back to reference Ogura K, Mizovaki T, Arakawa Y, Ogura M, Sakanaka K, Miyamoto S, et al. Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemotherapy and salvage treatment: a retrospective cohort study in a single institution. Radiat Oncol. 2013;8:97.CrossRefPubMedPubMedCentral Ogura K, Mizovaki T, Arakawa Y, Ogura M, Sakanaka K, Miyamoto S, et al. Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemotherapy and salvage treatment: a retrospective cohort study in a single institution. Radiat Oncol. 2013;8:97.CrossRefPubMedPubMedCentral
18.
go back to reference Wen P, MacDonald D, Reardon D, Cloughesy T, Sorensen A, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963–72.CrossRefPubMed Wen P, MacDonald D, Reardon D, Cloughesy T, Sorensen A, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963–72.CrossRefPubMed
19.
go back to reference Wagner D, Christiansen H, Wolff H, Vorwerk H. Radiotherapy of malignant gliomas: comparison of volumetric single arc technique (RapidArc), dynamic intensity-modulated technique and 3D conformal technique. Radiother Oncol. 2009;93:593–6.CrossRefPubMed Wagner D, Christiansen H, Wolff H, Vorwerk H. Radiotherapy of malignant gliomas: comparison of volumetric single arc technique (RapidArc), dynamic intensity-modulated technique and 3D conformal technique. Radiother Oncol. 2009;93:593–6.CrossRefPubMed
20.
go back to reference Shaffer R, Nichol AM, Vollans E, Fong M, Nakano S, Moiseenko V, et al. A comparison of volumetric modulated arc therapy and conventional intensity-modulated radiotherapy for frontal and temporal high-grade gliomas. Int J Radiat Oncol Biol Phys. 2010;76:1177–84.CrossRefPubMed Shaffer R, Nichol AM, Vollans E, Fong M, Nakano S, Moiseenko V, et al. A comparison of volumetric modulated arc therapy and conventional intensity-modulated radiotherapy for frontal and temporal high-grade gliomas. Int J Radiat Oncol Biol Phys. 2010;76:1177–84.CrossRefPubMed
21.
go back to reference Hermanto U, Frija E, Lii M, Chang E, Mahajan A, Woo S. Intensity modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: does IMRT increase the integral dose to normal brain? Int J Radiat Oncol Biol Phys. 2007;67:1135–44.CrossRefPubMed Hermanto U, Frija E, Lii M, Chang E, Mahajan A, Woo S. Intensity modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: does IMRT increase the integral dose to normal brain? Int J Radiat Oncol Biol Phys. 2007;67:1135–44.CrossRefPubMed
22.
go back to reference Narayana A, Yamada J, Berry S, Shah P, Hunt M, Gutin P, et al. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetrical results. Int J Radiat Oncol Biol Phys. 2006;64:892–7.CrossRefPubMed Narayana A, Yamada J, Berry S, Shah P, Hunt M, Gutin P, et al. Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetrical results. Int J Radiat Oncol Biol Phys. 2006;64:892–7.CrossRefPubMed
23.
go back to reference Chan M, Schupak K, Burman C, Chui C, Ling C. Comparison of intensity modulated radiotherapy with three-dimensional conformal radiation therapy planning for glioblastoma multiforme. Med Dosim. 2003;28:261–5.CrossRefPubMed Chan M, Schupak K, Burman C, Chui C, Ling C. Comparison of intensity modulated radiotherapy with three-dimensional conformal radiation therapy planning for glioblastoma multiforme. Med Dosim. 2003;28:261–5.CrossRefPubMed
24.
go back to reference Zach L, Stall B, Ning H, Ondos J, Arora B, Uma S, et al. A dosimetric comparison of four treatment planning methods for high grade glioma. Radiat Oncol. 2009;4:45.CrossRefPubMedPubMedCentral Zach L, Stall B, Ning H, Ondos J, Arora B, Uma S, et al. A dosimetric comparison of four treatment planning methods for high grade glioma. Radiat Oncol. 2009;4:45.CrossRefPubMedPubMedCentral
25.
go back to reference Piroth M, Pinkawa M, Holy R, Stoffels G, Demirel C, Attieh C, et al. Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme—a dosimetric comparison. Radiat Oncol. 2009;4:57.CrossRefPubMedPubMedCentral Piroth M, Pinkawa M, Holy R, Stoffels G, Demirel C, Attieh C, et al. Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme—a dosimetric comparison. Radiat Oncol. 2009;4:57.CrossRefPubMedPubMedCentral
26.
go back to reference Lorentini S, Amelio D, Giri M, Fellin f, Meliardo G, Rizzotti A, et al. IMRT or 3D-CRT in glioblastoma? a dosimetric criterion for patient selection. Tech Canc Res Treat. 2013;5:411–20. Lorentini S, Amelio D, Giri M, Fellin f, Meliardo G, Rizzotti A, et al. IMRT or 3D-CRT in glioblastoma? a dosimetric criterion for patient selection. Tech Canc Res Treat. 2013;5:411–20.
27.
go back to reference MacDonald S, Ahmad S, Kachris S, Vogds B, Derouen M, Gittleman A, et al. Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison. J Appl Clin Med Phys. 2008;8:47–60. MacDonald S, Ahmad S, Kachris S, Vogds B, Derouen M, Gittleman A, et al. Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison. J Appl Clin Med Phys. 2008;8:47–60.
Metadata
Title
Can advanced new radiation therapy technologies improve outcome of high grade glioma (HGG) patients? analysis of 3D-conformal radiotherapy (3DCRT) versus volumetric-modulated arc therapy (VMAT) in patients treated with surgery, concomitant and adjuvant chemo-radiotherapy
Authors
Pierina Navarria
Federico Pessina
Luca Cozzi
Anna Maria Ascolese
Francesca Lobefalo
Antonella Stravato
Giuseppe D’Agostino
Ciro Franzese
Manuela Caroli
Lorenzo Bello
Marta Scorsetti
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2399-6

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine